COVID-19 Impact on Ophthalmic Drugs Market Size to Hit $42.6 Billion by 2023

UPDATE AVAILABLE ON-DEMAND

“Rising incidence of glaucoma, cataract, and retinal disorders across the globe has propelled key market players to develop novel and effective ocular therapies. The geriatric population is prone to ophthalmic diseases such as age-related macular degeneration and diabetic retinopathy; thus, growth in this population is set to drive the ophthalmic drugs market.”

The Global Ophthalmic Drugs Market was valued at $29.6 billion in 2016, and is projected to reach $42.6 billion by 2023, growing at a CAGR of 5.3% from 2017 to 2023. The retinal disorders segment accounted for 26.6% of the global ophthalmic drugs market in 2016.

The development of effective ophthalmic is crucial is the current scenario, owing to increase in incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. Ophthalmic drugs are administered in different dosage forms depending upon the indication. Market players focus on innovation of novel approaches for the development of ophthalmic drugs over the years, including small molecule, biologics, and recombinant technologies, thereby driving the growth of ophthalmic drugs market.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/310

Global Ophthalmic Drugs Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report.

Increase in focus towards developing combination therapies for treatment of ophthalmic disorders, prevalence of these disorders, and surge in geriatric population are projected to drive the ophthalmic drugs market growth. In addition, continuous change in demographics worldwide supplements this growth. However, longer timelines required for the approval of novel ophthalmic drugs and side effects associated with the same limit market expansion.

Conversely, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma globally are anticipated to offer lucrative opportunities for market expansion. The multicompartment drug delivery systems is expected to witness a CAGR of 8.0% from 2017 to 2023, as these systems are ideal to sustain and deliver therapeutics to the target tissues and cells. The anti-inflammatory segment accounted for 28% of ophthalmic drugs market share in 2016, and is projected to continue its dominance throughout the forecast period.

Among distribution channel, hospital pharmacies generated the highest revenue in 2016, accounting for 31% of the total ophthalmic drugs market share, and are anticipated to continue this trend throughout the forecast period. Moreover, online pharmacies segment is expected to witness a high growth rate of 5.8%, owing to increase in trend of online ordering and easy availability of drugs.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/310

Asia-Pacific is expected to witness highest growth rate for ophthalmic drugs throughout the forecast period, and is expected to continue this trend, owing to high population density, increase in geriatric population, and rise in incidence of congenital glaucoma and cataract in India and China.

Major Key players added in the Ophthalmic Drugs Market have adopted product launch as one of their key developmental strategies, among others such as business expansion, product development, and business acquisition.

The Major Key Players Are:

Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis), Genentech, Inc. Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.

Scope Of The Report

Report Attribute	Details
Market size available for years	2017-2023
Base year considered	2018
Forecast period	2018-2023
Forecast units	Value (USD)
Segments covered	By Indication, Dosage Form, Technology, Distribution Channel, and Therapeutic Class
Geographies covered	North America, Europe, Asia-Pacific, LAMEA

Related Reports:

Ophthalmic Lasers Market – Global Opportunity Analysis and Industry Forecast, 2017-2023

Ophthalmic Surgery Devices Market – Global Opportunity Analysis and Industry Forecast, 2019-2026

Antifibrinolytic Drugs Market – Global Opportunity Analysis and Industry Forecast, 2019–2026